Reynolds Rebecca M
Endocrinology Unit, University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, Edinburgh, UK.
Clin Obstet Gynecol. 2013 Sep;56(3):602-9. doi: 10.1097/GRF.0b013e31829939f7.
Fetal glucocorticoid overexposure is a key potential mechanism underlying the link between low birthweight and later life diseases. The fetus is protected from high maternal glucocorticoid levels by the placental enzyme 11β-hydroxysteroid dehydrogenase type 2. Antenatal glucocorticoid administration to women at threat of preterm labor, and high endogenous maternal glucocorticoid levels during pregnancy associate with lower birthweight. Long-term consequences for offspring include hypothalamic-pituitary-adrenal axis activation, increased metabolic and cardiovascular disorders, and neurodevelopmental sequelae. Strategies are needed to limit antenatal glucocorticoid use to those most at risk of preterm labor and to identify those most at risk of future disease.
胎儿糖皮质激素过度暴露是低出生体重与成年后疾病之间联系的关键潜在机制。胎盘2型11β-羟基类固醇脱氢酶可保护胎儿免受母体高糖皮质激素水平的影响。对有早产风险的妇女进行产前糖皮质激素给药,以及孕期母体糖皮质激素内源性水平升高与较低出生体重相关。对后代的长期影响包括下丘脑-垂体-肾上腺轴激活、代谢和心血管疾病增加以及神经发育后遗症。需要采取策略将产前糖皮质激素的使用限制在早产风险最高的人群,并识别那些未来疾病风险最高的人群。